Monthly information regarding the total number of voting rights and total number of shares of the CompanyGlobeNewsWire • 01/14/20
DBV Technologies Reports Positive Three-Year, Long-Term Data from the PEOPLE Phase III Open-Label Extension Study of Viaskin Peanut in Children with Peanut AllergyGlobeNewsWire • 01/08/20
DBV Technologies Announces Appointment of Ramzi Benamar as Chief Financial OfficerGlobeNewsWire • 01/02/20
DBV Technologies: Selloff Provides Attractive Entry, Big Upside Ahead Of Expected Drug ApprovalSeeking Alpha • 12/26/19
Monthly information regarding the total number of voting rights and total number of shares of the CompanyGlobeNewsWire • 11/19/19
DBV Technologies to Highlight the Burden of Peanut Allergy and Patient Experiences with Viaskin Peanut at ACAAI 2019GlobeNewsWire • 10/24/19
DBV Technologies Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares in the Form of American Depositary Shares (ADSs)GlobeNewsWire • 10/10/19
Mise à disposition d’un prospectus dans le cadre de l’admission d’actions nouvelles sur Euronext ParisGlobeNewsWire • 10/09/19
DBV Technologies Announces Pricing of $125 million (€114 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary SharesGlobeNewsWire • 10/09/19
DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares, and Reports September 30, 2019 Cash PositionGlobeNewsWire • 10/08/19
DBV Technologies Announces FDA Acceptance of BLA filing for Viaskin Peanut for the Treatment of Peanut AllergyGlobeNewsWire • 10/04/19
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital socialGlobeNewsWire • 09/19/19
DBV Technologies S.A. (DBVT) Moves to Buy: Rationale Behind the UpgradeZacks Investment Research • 06/12/19
DBV Technologies S.A. (DBVT) Shares March Higher, Can It Continue? Zacks Investment Research • 04/11/19